Phase IV, open-label, multicentre trial of afatinib in patients (pts) aged ≥70 yrs with NSCLC harbouring common (Del19/L858R) EGFR mutations: Preliminary results

被引：0
|
作者：
Reckamp, K. L. [1 ]
Gilman, P. [2 ]
Halmos, B. [3 ]
Jahanzeb, M. [4 ]
McCann, J. [5 ]
Paripati, H. [6 ]
Seneviratne, L. C. [7 ]
Wallace, J. A. [8 ]
Rueter, B. [9 ]
Esler, A. [10 ]
Dowling, E. [11 ]
Koczywas, M. [12 ]
机构：
[1] City Hope Comprehens Canc Ctr, Dept Med Oncol, Duarte, CA USA
[2] Lankenau Med Ctr, Canc Ctr, Wynnewood, PA USA
[3] Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, Bronx, NY 10467 USA
[4] Univ Miami, Sylvester Comprehens Canc Ctr, Deerfield Beach, FL USA
[5] DAmour Ctr Canc Care, Baystate Reg Canc Program, Springfield, MA USA
[6] Mayo Clin, Div Hematol Oncol, Phoenix, AZ USA
[7] Los Angeles Canc Network, Los Angeles Hematol Oncol Med Grp, Los Angeles, CA USA
[8] UChicago Med Ingalls, Dept Hematol Oncol & Geriatr, Harvey, IL USA
[9] Boehringer Ingelheim Pharmaceut Inc, CMDA Oncol, 90 E Ridge POB 368, Ridgefield, CT 06877 USA
[10] Syneos Hlth, Stat, Raleigh, NC USA
[11] Boehringer Ingelheim Pharmaceut Inc, Study Management & Conduct, 90 E Ridge POB 368, Ridgefield, CT 06877 USA
[12] City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1456P
引用
收藏
页码：527 / 527
页数：1
相关论文
共 21 条
  • [1] Plasma MiRNA alterations between NSCLC patients harboring Del19 and L858R EGFR mutations
    Ma, Yihan
    Xu, Peiqi
    Mi, Yanjun
    Wang, Wenyi
    Pan, Xiaoyan
    Wu, Xiaoting
    He, Qi
    Liu, Hongming
    Tang, Weiwei
    An, Hanxiang
    ONCOTARGET, 2016, 7 (34) : 54965 - 54972
  • [2] Phase IV study of afatinib as second-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring common epidermal growth factor receptor (EGFR) mutations (Del19 and/or L858R)
    Thongprasert, S.
    Alexandru, A.
    Schenker, M.
    Abdelaziz, A.
    Clement, D.
    Boldeanu, C.
    Jovanovic, D.
    Reyes-Igama, J.
    Petrovic, M.
    Geater, S.
    Radosavljevic, D.
    Perin, B.
    Krzakowski, M.
    Serwatowski, P.
    Parra, J.
    Sriuranpong, V.
    Jones, H.
    Cseh, A.
    Gaafar, R.
    ANNALS OF ONCOLOGY, 2015, 26 : 146 - 146
  • [3] Concomitant Mutations in EGFR 19Del/L858R Mutation and Their Association with Response to EGFR-TKIs in NSCLC Patients
    Liang, Hengrui
    Li, Caichen
    Zhao, Yi
    Zhao, Shen
    Huang, Jun
    Cai, Xiuyu
    Cheng, Bo
    Xiong, Shan
    Li, Jianfu
    Wang, Wei
    Zhu, Changbin
    Li, Weiwei
    He, Jianxing
    Liang, Wenhua
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 8653 - 8662
  • [4] Landscape of osimertinib resistant mutations between the two common subtypes of EGFR 19del or L858R in NSCLC.
    Zhang, Yan
    Zhao, Jun
    Guo, Renhua
    Lin, Gen
    Liu, Li
    Zhu, Chenchen
    Liang, Naixin
    Yang, Huaxia
    Wang, Wen xian
    Dai, Pingping
    Guan, Yan-Fang
    Yang, Ling
    Yi, Xin
    Xia, Xuefeng
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Gefitinib as first-line treatment for patients with NSCLC with activating EGFR mutationin exons 19 (Del19) or 21 (L858R) in the Czech Republic
    Skrickova, Jana
    Bortlicek, Zbynek
    Hejduk, Karel
    Pesek, Milos
    Kolek, Vitezslav
    Koubkova, Leona
    Roubec, Jaromir
    Havel, Libor
    Salajka, Frantisek
    Tomiskova, Marcela
    Satankova, Monika
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [6] High-dose Icotinib in Advanced NSCLC with EGFR 21 L858R Mutation: A Randomized, Open-Label Phase II Study
    Li, X.
    Zhang, L.
    Jiang, D.
    Wang, Y.
    Zang, A.
    Ding, C.
    Zhao, M.
    Su, W.
    Zhang, Y.
    Zhong, D.
    Wu, J.
    An, G.
    Zhang, C.
    Hu, X.
    Cheng, G.
    Wang, H.
    Han, Z.
    He, X.
    Liu, J.
    Liang, L.
    Zhang, S.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1049 - S1049
  • [7] Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut): Pooled analysis of two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT)
    Yang, James Chih-Hsin
    Sequist, Lecia V.
    Schuler, Martin H.
    Mok, Tony
    Yamamoto, Nobuyuki
    O'Byrne, Kenneth John
    Hirsh, Vera
    Geater, Sarayut Lucien
    Zhou, Caicun
    Massey, Dan
    Zazulina, Victoria
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Overall Survival (OS) With Afatinib Versus Chemotherapy in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring Common (Del19/L858R) Epidermal Growth Factor Receptor Mutations (EGFR Mut): Results of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)
    Sequist, L.
    Wu, Y.
    Schuler, M.
    O'Byrne, K.
    Sebastian, M.
    Popat, S.
    Boyer, M.
    Mok, T.
    Yamamoto, N.
    Hirsh, V.
    Geater, S. L.
    Zhou, C.
    Massey, D.
    Zazulina, V.
    Jones, H.
    Yang, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S5 - S6
  • [9] LUX-Lung 7: A Phase lib, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations
    Park, K.
    Tan, E. -H.
    Zhang, L.
    Hirsh, V.
    O'Byrne, K.
    Boyer, M.
    Yang, J.
    Mok, T.
    Kim, M.
    Paz-Ares, L.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S117 - S118
  • [10] EGFR analysis of 21,039 patients with NSCLC: Age-related gradual increase of the L858R mutation frequency in adenocarcinomas and high occurrence of ex19del/L858R mutations in squamous cell carcinomas from females and/or nonsmokers.
    Imianitov, Evgenii
    Demidova, Irina
    Gordiev, Marat
    Filipenko, Maxim
    Kekeeva, Tatiana
    Moliaka, Yuri
    Gervas, Polina
    Kozhemyako, Valeriy
    Vodolazhsky, Dmitriy I.
    Svetlana
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
123